Savara
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Summit Square 1717 Langhorne Newtown R...Phone Number
(512) 614-1848Website
www.savarapharma.comRevenue
$7.8 MillionStock Symbol
SVRAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.Explore more
Savara Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Savara your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Savara has new funding data
Click to see if Savara had a recent Job posting/layoffs
Check if Savara has recently received funding, and reach out quickly before it becomes old news!
Check out if Savara is spiking on competitors!
Savara, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Savara launches new products
Congratulate Masked Content for being promoted to Masked Content at Savara
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Savara recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Savara
Compare insights from companies similar to Savara, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Savara is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Savara is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Savara.
Savara financials insights
Gather financial insights about Savara, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Stock Offering
$15.7M
2013
Series B
$17.3M
2016
Series C
$20M
2017
Multiple Rounds
$70M
2018
Stock Offering
$48.9M
2019
Share Placement
$26.8M
2022
Debt
$26.5M
Savara Tech Stack
A closer look at the technologies used by Savara
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Earnings
Earnings, Finance
Person-Based
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Pharmaceuticals, Pricing
Savara News & Media
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears
Savara (NASDAQ:SVRA) executives highlighted recent regulatory and commercial milestones for its lead program, molgramostim inhalation solution (Molbreevi), during a discussion at Oppenheimer’s 36th Annual Healthcare Life Science Conference. Management said the U.S. Food and Drug Administration (FDA)Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Savara Inc. (SVRA) 44th Annual J.P.With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest
Key Insights Given the large stake in the stock by institutions, Savara's stock price might be vulnerable to their...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Savara
Sign Up For FreeTo access detailed company insights
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Neb... Read More
